Literature DB >> 3927867

Pseudomonas bacteremia. Retrospective analysis of 410 episodes.

G P Bodey, L Jadeja, L Elting.   

Abstract

We reviewed 410 episodes of Pseudomonas bacteremia occurring in patients with cancer during a ten-year period. Pseudomonas bacteremia was most common among patients with acute leukemia. The majority of patients acquired their infections in the hospital, and 51% had received antibiotic therapy for other presumed or proved infection during the preceding week. Shock occurred in 33%, and 32% had concomitant pneumonia. The overall cure rate was 62%; it was 67% for patients receiving appropriate antibiotics but only 14% for those receiving inappropriate antibiotics. A one- to two-day delay in the administration of appropriate antibiotic therapy reduced the cure rate from 74% to 46%. Patients who received an antipseudomonal beta-lactam antibiotic with or without an aminoglycoside had a significantly higher cure rate than patients who received only an aminoglycoside (72% and 71% vs 29%). Patients with shock, pneumonia, or persistent neutropenia had a substantially poorer prognosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3927867     DOI: 10.1001/archinte.145.9.1621

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  79 in total

1.  Pseudomonas aeruginosa sepsis and ecthyma gangrenosum as initial manifestations of primary immunodeficiency.

Authors:  María Baro; Miguel Angel Marín; Jesús Ruiz-Contreras; Sira Fernandez de Miguel; Ignacio Sánchez-Díaz
Journal:  Eur J Pediatr       Date:  2003-12-20       Impact factor: 3.183

2.  Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.

Authors:  Eric Chamot; Emmanuelle Boffi El Amari; Peter Rohner; Christian Van Delden
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

Review 3.  Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance.

Authors:  C Andrew DeRyke; Su Young Lee; Joseph L Kuti; David P Nicolau
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations.

Authors:  Sheryl Zelenitsky; Robert Ariano; Godfrey Harding; Alan Forrest
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

5.  Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection.

Authors:  Thomas P Lodise; Nimish Patel; Andrea Kwa; Jeffrey Graves; Jon P Furuno; Eileen Graffunder; Ben Lomaestro; Jessina C McGregor
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

Review 6.  Antimicrobial agent therapy for Pseudomonas aeruginosa.

Authors:  J A Korvick; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

7.  Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?

Authors:  Ping-Feng Wu; Yi-Tsung Lin; Fu-Der Wang; Tsuey-Ching Yang; Chang-Phone Fung
Journal:  Infection       Date:  2018-03-20       Impact factor: 3.553

8.  Nosocomial septicemias due to methicillin-resistant staphylococcus aureus and Pseudomonas aeruginosa in a university hospital over a 12-year period--the same intractable infections.

Authors:  Y Mizushima; H Li; I Yoshida; K Sassa; T Hamazaki; M Kobayashi
Journal:  Infection       Date:  1996 May-Jun       Impact factor: 3.553

9.  Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection.

Authors:  M D Parkins; D B Gregson; J D D Pitout; T Ross; K B Laupland
Journal:  Infection       Date:  2009-12-12       Impact factor: 3.553

10.  The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies.

Authors:  Michael J Satlin; Stephen G Jenkins; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2014-01-23       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.